Tonix Pharmaceuticals Inc. (NASDAQ:TNXP) shares are down during Tuesday's premarket session following the company's recent uplisting to the Nasdaq Global Select Market. The transition reflects compliance with higher financial and corporate governance standards, potentially enhancing visibility among institutional investors and improving liquidity as the broader market experienced declines. TNXP Price Action: Tonix Pharmaceuticals shares were down 2% at $13.70 during premarket trading on Tuesday, according t ...